Anti-inflammatory peptides KPV BPC-157 GHK-Cu research Durham Peptides Canada Inflammation research is one of the most active areas in modern biomedical science, and several research peptides have been studied extensively for their effects on inflammatory pathways. The category isn't homogeneous — different peptides engage different aspects of the inflammatory response through distinct molecular mechanisms. Understanding how these mechanisms differ helps researchers match the

Tesamorelin sermorelin CJC-1295 GHRH analog comparison Durham Peptides Canada The growth hormone-releasing hormone (GHRH) analog category contains three compounds that dominate the published research literature: sermorelin, CJC-1295, and tesamorelin. All three engage the same receptor — the GHRH receptor on pituitary somatotroph cells — but each takes a structurally distinct approach to extending the practical research half-life of native GHRH. For Canadian researchers enteri

Tesamorelin GHRH analog peptide research Durham Peptides Canada Tesamorelin occupies a distinctive position in the peptide research field. Unlike most research peptides, tesamorelin has a substantial pharmaceutical research history — it's an approved medication in some jurisdictions for specific indications — alongside an active research peptide presence. This dual status makes it one of the more thoroughly characterized peptides researchers can work with, with both clinical

KPV peptide anti-inflammatory tripeptide research Durham Peptides Canada KPV is one of the smallest peptides in the entire research peptide field — just three amino acids — but the published research literature on it has accumulated steadily over more than three decades. As the C-terminal tripeptide fragment of α-melanocyte-stimulating hormone (α-MSH), KPV has been investigated extensively for anti-inflammatory effects in published preclinical research. Its addition as the fo

DSIP delta sleep-inducing peptide research Durham Peptides Canada Delta Sleep-Inducing Peptide (DSIP) occupies an unusual corner of the peptide research field. Discovered in the 1970s during sleep research, DSIP has accumulated decades of published literature without becoming a mainstream research peptide in the way that BPC-157, GHK-Cu, or the metabolic peptides have. The compound's research history spans neuropeptide biology, sleep architecture research, stress response stu

Peptide manufacturing process SPPS solid-phase synthesis Durham Peptides Canada Most discussions of research peptide quality focus on the end-of-pipeline stage — Certificates of Analysis, HPLC purity, mass spectrometry identity confirmation. But understanding what those quality measurements are actually measuring requires understanding the upstream process that produces the peptide in the first place. The manufacturing approach determines what kinds of impurities can exist, w

PT-141 bremelanotide melanocortin peptide research Durham Peptides Canada PT-141 (also known as bremelanotide) is a synthetic peptide that has accumulated a substantive published research literature in a distinct corner of the peptide field — the melanocortin receptor system. Unlike the metabolic peptides that dominate current research conversations, PT-141 works through a receptor pathway that connects to skin pigmentation biology, neural signaling, and several other researc

Peptide research trends 2026 emerging compounds future Durham Peptides Canada The peptide research field in 2026 looks fundamentally different from where it was even three years ago. Compounds that were Phase 1 candidates in 2023 are now in Phase 3 or approved. Receptor combinations that didn't exist as research targets are now central. The regulatory landscape has shifted in ways that affect the entire international supply chain. And several emerging peptide categories — onc

Peptide stacking guide BPC-157 TB-500 GHK-Cu combination research Durham Peptides Canada The term "peptide stacking" gets used loosely in the broader peptide community, often as marketing language for selling multiple peptides together. The actual research basis is more interesting and more specific. When researchers combine peptides in study protocols, the rationale isn't "more peptides = better results." It's about engaging multiple biological pathways simultaneously, where

How to verify peptide quality COA third-party testing Janoshik Durham Peptides Canada In the research peptide market, quality claims are easy to make and hard to verify. Every supplier claims their peptides are pure. Every product page mentions "lab-tested." Every website talks about quality control. The actual question — how a researcher can independently confirm that the vial they receive contains what its label claims, at the purity level claimed, manufactured the way clai

Peptide glossary research terminology Durham Peptides Canada Peptide research operates at the intersection of biochemistry, pharmacology, manufacturing, regulatory affairs, and quality control — and each of these fields has its own vocabulary. Researchers new to the peptide space often encounter the same problem: a single product page or COA can contain a dozen acronyms and technical terms, each one assuming the reader already knows what it means. This glossary is designed to

Cagrilintide amylin analog peptide research Durham Peptides Canada The conversation around metabolic peptide research has been dominated for several years by GLP-1 receptor agonists (semaglutide), dual agonists (tirzepatide), and triple agonists (retatrutide). But a separate research thread has been advancing in parallel: amylin analog research, with cagrilintide as the leading compound. When combined with semaglutide in the formulation known as CagriSema, cagrilintide has pr

Growth hormone peptides sermorelin CJC-1295 ipamorelin research Durham Peptides Canada Among research peptide categories, growth hormone-releasing peptides occupy a distinct position. They don't directly add growth hormone to the body — instead, they act on the body's own hormone-producing machinery, modulating the natural pulsatile release pattern that the pituitary gland uses to regulate growth hormone signaling. Three compounds dominate the published research literature in

Peptide half life pharmacokinetics research Durham Peptides Canada One of the most consequential differences between research peptides is the simplest to overlook: half-life. Semaglutidehas a half-life of roughly seven days. BPC-157 clears the bloodstream in hours. Sermorelin, discussed in the broader growth hormone peptide research literature, is measured in minutes. These are not minor variations — they shape how every research protocol is designed, how often researchers do

Copper peptides GHK-Cu copper-bound peptide research Durham Peptides Canada "Copper peptides" is a category of research compounds that bridges peptide biology with bioinorganic chemistry. Unlike most research peptides — which are built entirely from amino acids — copper peptides include a bound copper ion as a structural component. This combination produces compounds with distinct biological properties that neither the peptide alone nor the copper alone would produce. This ar

Semaglutide vs tirzepatide comparison Canadian research peptides Durham Peptides "Semaglutide vs tirzepatide" is one of the most-searched comparison queries in the Canadian research peptide market, and for good reason. The two compounds sit at the center of the incretin peptide class — the research area that has produced more clinical trial data than any other peptide category in the past decade. For Canadian researchers entering the metabolic peptide space, understanding the

Triple agonist peptides retatrutide GLP-3 research Durham Peptides Canada Few peptide categories have moved as fast as triple agonist metabolic peptides. In less than a decade, the field has progressed from single-receptor compounds (semaglutide) to dual-receptor compounds (tirzepatide) to the first triple-receptor agonist — retatrutide — currently in advanced clinical trials. Each generation has generated more research attention than the last, and the terminology has evolved

Andrew Huberman peptides research podcast discussion Durham Peptides Canada Few scientific communicators have done more to bring peptide research into mainstream awareness than Dr. Andrew Huberman. As a tenured professor of neurobiology and ophthalmology at Stanford School of Medicine, and the host of the Huberman Lab podcast, his audience of millions of listeners has shaped how a generation of researchers, biohackers, and health-curious individuals think about peptides. Wher

FDA peptide reclassification 2026 PCAC review Durham Peptides Canada On April 15, 2026, the US Food and Drug Administration issued a federal notice announcing that the Pharmacy Compounding Advisory Committee (PCAC) will convene on July 23-24, 2026, to evaluate seven peptide compounds in the context of US compounding pharmacy regulation. The announcement has received substantial coverage across US health and regulatory news outlets, with particular attention to compounds that

Is tirzepatide a peptide research classification Durham Peptides Canada "Is tirzepatide a peptide?" is one of the most frequently asked questions by researchers and buyers entering the metabolic research space for the first time. The short answer is yes — tirzepatide is a peptide. But because tirzepatide is most commonly encountered under its brand names (Mounjaro and Zepbound) as an approved pharmaceutical, it's often not immediately obvious to people outside the research co